左卡尼汀氯化物(Levocarnitine Chloride) - 在研适应症：全身性肉碱缺乏症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Levocarnitine chloride (JAN)、L-cartin

靶点-

作用机制-

治疗领域

神经系统疾病心血管疾病皮肤和肌肉骨骼疾病+ [1]

在研适应症

全身性肉碱缺乏症

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C7H16ClNO3

InChIKeyJXXCENBLGFBQJM-FYZOBXCZSA-N

CAS号6645-46-1

关联

2

项与左卡尼汀氯化物相关的临床试验

CTRI/2022/10/046683 / Not yet recruiting临床3期IIT

Role of Levocarnitine (L-Carnitine) Supplementation on recovery in children with Complicated Severe Acute Malnutrition: A Randomized Double Blind Placebo Controlled Trial

开始日期2023-03-01

申办/合作机构

Indian Council of Medical Research

JPRN-UMIN000007650 / RecruitingN/AIIT

Efficacy of levocarnitine chloride for myocardial fatty acid metabolism in dialysis patients - levocarnitine chloride and myocardial fatty acid metabolism

开始日期2012-02-01

申办/合作机构-

100 项与左卡尼汀氯化物相关的临床结果

登录后查看更多信息

100 项与左卡尼汀氯化物相关的转化医学

登录后查看更多信息

100 项与左卡尼汀氯化物相关的专利（医药）

登录后查看更多信息

17

项与左卡尼汀氯化物相关的文献（医药）

2014-10-01·Gan to kagaku ryoho. Cancer & chemotherapy

[Experience with levocarnitine chloride supplementation for the treatment of fatigue in cancer patients undergoing chemotherapy].

Article

作者: Nakagawa, Yasuo ; Matsunaga, Nobuo ; Yanagawa, Kenichi

AIMPatients undergoing chemotherapy are at risk of carnitine deficiency, and carnitine supplementation has been demonstrated to improve cancer-related fatigue. We examined the changes in fatigue when cancer patients experiencing fatigue while undergoing chemotherapy were administered levocarnitine chloride.MATERIALS AND METHODSTen patients with advanced and recurrent cancer experiencing fatigue during chemotherapy were administered levocarnitine chloride. We investigated changes in fatigue, and carried out nutritional assessment using the numerical rating scale(NRS)and geriatric nutritional risk index(GNRI), before and after levocarnitine chloride treatment.RESULTSFour patients responded to levocarnitine chloride treatment, while six did not. Before treatment, the GNRI of responders was significantly lower than that of nonresponders. The difference between the two groups disappeared after treatment.CONCLUSIONA form of malnutrition may have been present in responders, which may have been improved by carnitine supplementation. It is possible that an improvement in this nutritional disorder was involved in fatigue mitigation.

2014-06-01·Clinical Kidney Journal3区 · 医学

Trimethylamine generation in patients receiving hemodialysis treated with L-carnitine

3区 · 医学

ArticleOA

作者: Koizumi, Ayano ; Shimizu, Makiko ; Ozasa, Hisashi ; Wakabayashi, Akari ; Yamazaki, Hiroshi

Hepatic biotransformation of gut microbiota-derived trimethylamine (TMA) to trimethylamine N-oxide (TMAO) may enhance cardiovascular risk [1, 2]. The source of TMA is fish-derived TMAO [3], meat-derived betaine/choline/phosphatidylcholine [1, 2], and the medicine l-carnitine [4]. There is no clear information on the metabolic fate of TMA/TMAO in patients receiving hemodialysis and treated with l-carnitine orally and intravenously. We report data showing that plasma TMA/TMAO concentrations in hemodialysis patients may be in the same range as those of healthy subjects consuming a typical diet in Japan. Fourteen subjects, randomly selected from a cohort of 18 male and 6 female Japanese patients (47–89 years) with diabetes mellitus or chronic glomerulonephritis who had undergone hemodialysis for several years, were divided into five untreated controls, five treated with 1000 mg of l-carnitine (l-Cartin injection, Otsuka, Tokyo, Japan) intravenously on 3 days (Days 1, 3 and 5) over 1 week, and four treated with 300 mg of oral l-carnitine (l-Cartin tablets, Otsuka) three times per day for 7 days. Ten healthy volunteers (22–59 years) were also enrolled. This study was approved by the ethics committees of Minami Ikebukuro Clinic and Showa Pharmaceutical University. Total carnitine and TMA/TMAO concentrations were determined by Kainos laboratories (Tokyo, Japan) and by gas chromatography [3]. Carnitine concentrations for 2–8 weeks after treatment with l-carnitine were significantly higher than those in the untreated group (Figure 1). Plasma TMA concentrations after oral treatment with l-carnitine were higher than those of the untreated group. TMAO concentrations did not increase significantly after treatments and were in the range of daily interindividual variations. In separate observations in 22 of the 24-patient cohort, pre-dialysis plasma concentrations of carnitine (33 ± 4 µM, mean ± SD), TMA (34 ± 20 µM) and TMAO (189 ± 94 µM) were decreased by hemodialysis (12 ± 8, 25 ± 8 and 140 ± 77 µM, respectively). These concentration ranges were comparable with TMA (26 ± 17 µM) and TMAO (197 ± 100 µM) in healthy volunteers (n = 10). The present plasma levels of TMA and/or TMAO in Japanese patients were one or two orders of magnitude higher than the reported concentrations in Caucasians [1, 2], but were consistent with a review of patients undergoing hemodialysis [4]. Fig. 1. Plasma concentrations of total l-carnitine (A), TMA (B) and TMAO (C) in untreated patients (circles) and in patients treated with l-carnitine intravenously (triangles) and orally (squares). The three bars are averages of the three groups (n = 4 or 5). ... Some TMA formation in a Japanese cohort treated with l-carnitine orally was confirmed, but the levels of TMA/TMAO both pre-/post-dialysis in patients not receiving l-carnitine were in the same ranges as those of the control subjects.

2013-09-01·Cell Biochemistry and Biophysics4区 · 生物学

Novel c.2216T > C (p.I739T) Mutation in Exon 13 and c.1481T > A (p.L494X) Mutation in Exon 8 of MUT Gene in a Female with Methylmalonic Acidemia

4区 · 生物学

Article

作者: Yuki Omura-Hasegawa ; George Imataka ; Osamu Arisaka ; Shigemi Yoshihara ; Hideo Yamanouchi ; Go Tajima ; Osamu Sakamoto

We report herein a 1.5-year-old girl with methylmalonic acidemia (MMA) in whom two missense mutations were found: a novel I739T mutation located in exon 13 and the L494X mutation in exon 8. The results of organic acid test showed a pronounced increase in methylmalonate excretion with increased methylcitrate and 3-OH-propionate excretion, leading to a diagnosis of MMA, and Vitamin B12 administration was started. Analysis of the mut gene confirmed a T-to-A substitution at nucleotide position 1481 in exon 8 and a T-to-C substitution at nucleotide position 2216 in exon 13, leading to the amino acid isoleucine at position 739 being changed to threonine, resulting in c.2216T > C (p.I739T). The patient has now been on high-dose oral administration of Vitamin B12 and carnitine therapy (900 mg of levocarnitine chloride) for 5 years without experiencing further attacks, and her cognitive and motor development is normal. Further tests on residual enzyme activity, as well as experience with more cases, may shed light on the relationship between gene mutations and phenotypes in MMA.

100 项与左卡尼汀氯化物相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02030	-	A16AA01	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
全身性肉碱缺乏症	-	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SP619 (ERA2016)	N/A	carnitine deficiency	166	Levocarnitine chloride	遞糧夢簾憲鑰糧淵醖獵(鑰蓋廠鹹夢襯製衊窪觸) = 鹽製餘鏇壓簾鏇積選鹽願簾淵膚襯願鑰繭積艱 (廠壓築遞範製鑰鏇獵築, 151.9)	积极	2016-05-14
				No levocarnitine chloride	遞糧夢簾憲鑰糧淵醖獵(鑰蓋廠鹹夢襯製衊窪觸) = 夢鹽鬱範鏇衊艱製衊夢願簾淵膚襯願鑰繭積艱 (廠壓築遞範製鑰鏇獵築, 4.6)